Literature DB >> 28767222

Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation.

Philipp Ottis1, Momar Toure1, Philipp M Cromm1, Eunhwa Ko1, Jeffrey L Gustafson1, Craig M Crews1,2,3.   

Abstract

Proteolysis targeting chimera (PROTAC) technology, the recruitment of E3 ubiquitin ligases to induce the degradation of a protein target, is rapidly impacting chemical biology, as well as modern drug development. Here, we explore the universality of this approach by evaluating different E3 ubiquitin ligases, engineered in their substrate binding domains to accept a recruiting ligand. Five out of six E3 ligases were found to be amenable to recruitment for target degradation. Taking advantage of the tight spatiotemporal control of inducing ubiquitination on a preselected target in living cells, we focused on two of the engineered E3 ligases, βTRCP and parkin, to unravel their ubiquitination characteristics in comparison with the PROTAC-recruited endogenous E3 ligases VHL and cereblon.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28767222     DOI: 10.1021/acschembio.7b00485

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  35 in total

1.  Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA.

Authors:  Matthew G Costales; Blessy Suresh; Kamalakannan Vishnu; Matthew D Disney
Journal:  Cell Chem Biol       Date:  2019-05-23       Impact factor: 8.116

2.  Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

Authors:  Daniel P Bondeson; Blake E Smith; George M Burslem; Alexandru D Buhimschi; John Hines; Saul Jaime-Figueroa; Jing Wang; Brian D Hamman; Alexey Ishchenko; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

Review 3.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

4.  The Evolving Druggability and Developability Space: Chemically Modified New Modalities and Emerging Small Molecules.

Authors:  Wenzhan Yang; Prajakta Gadgil; Venkata R Krishnamurthy; Margaret Landis; Pankajini Mallick; Dipal Patel; Phenil J Patel; Darren L Reid; Manuel Sanchez-Felix
Journal:  AAPS J       Date:  2020-01-03       Impact factor: 4.009

5.  Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.

Authors:  Shang Su; Zimo Yang; Hongying Gao; Haiyan Yang; Songbiao Zhu; Zixuan An; Juanjuan Wang; Qing Li; Sarat Chandarlapaty; Haiteng Deng; Wei Wu; Yu Rao
Journal:  J Med Chem       Date:  2019-08-02       Impact factor: 7.446

Review 6.  Targeted protein degradation: elements of PROTAC design.

Authors:  Stacey-Lynn Paiva; Craig M Crews
Journal:  Curr Opin Chem Biol       Date:  2019-04-17       Impact factor: 8.822

7.  Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.

Authors:  Sarah D Mahan; Kristin M Riching; Marjeta Urh; Danette L Daniels
Journal:  Methods Mol Biol       Date:  2021

Review 8.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

9.  MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.

Authors:  John Hines; Schan Lartigue; Hanqing Dong; Yimin Qian; Craig M Crews
Journal:  Cancer Res       Date:  2018-11-01       Impact factor: 12.701

Review 10.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.